# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACRONYMS</td>
<td>1</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>2</td>
</tr>
<tr>
<td>STATEMENT of PURPOSE</td>
<td>3</td>
</tr>
<tr>
<td>INSTITUTIONAL BIOSAFETY COMMITTEE MEETING SUPPORT</td>
<td>5</td>
</tr>
<tr>
<td>STRUCTURE of the INSTITUTIONAL BIOSAFETY COMMITTEE</td>
<td>6</td>
</tr>
<tr>
<td>APPOINTMENT PROCESS and LENGTH of SERVICE</td>
<td>7</td>
</tr>
<tr>
<td>PROCEDURES for DEFINING a QUORUM</td>
<td>8</td>
</tr>
<tr>
<td>MEETING SCHEDULE</td>
<td>9</td>
</tr>
<tr>
<td>MINUTES POLICY</td>
<td>10</td>
</tr>
<tr>
<td>CONFLICT of INTEREST</td>
<td>11</td>
</tr>
<tr>
<td>PROTOCOL REVIEWS</td>
<td>12</td>
</tr>
<tr>
<td>LABORATORY CONTAINMENT and SAFETY</td>
<td>16</td>
</tr>
<tr>
<td>HEALTH SURVEILLANCE PROGRAM</td>
<td>17</td>
</tr>
<tr>
<td>INSTITUTIONAL BIOSAFETY COMMITTEE VOTING</td>
<td>18</td>
</tr>
<tr>
<td>PROTECTING CONFIDENTIAL INFORMATION</td>
<td>19</td>
</tr>
<tr>
<td>INSTITUTIONAL BIOSAFETY COMMITTEE MEMBERSHIP</td>
<td>20</td>
</tr>
<tr>
<td>INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>• Move intravenous infected <em>M. tuberculosis</em> mice from BSL 3 to BSL 2</td>
<td>21</td>
</tr>
<tr>
<td>• Declassify <em>M. tuberculosis</em> mutants MC^6030 and MC^60020 from BSL 3 to BSL 2</td>
<td>21</td>
</tr>
<tr>
<td>• Guidance for in-servicing of the Madison Wisconsin Chamber</td>
<td>21</td>
</tr>
<tr>
<td>• Allow Dr. Arturo Casadevall to work with <em>Bacillus anthracis</em> Sterne Strain</td>
<td>21</td>
</tr>
<tr>
<td>• Allow Dr. Arturo Casadevall to work with <em>Bacillus anthracis</em> Pasteur Strain</td>
<td>21</td>
</tr>
<tr>
<td>• Guidance in FACS sorting unfixed cells</td>
<td>21</td>
</tr>
<tr>
<td>• Allow Dr. Margaret Kielian to continue working with Semliki Forest virus at enhanced BSL 2</td>
<td>21</td>
</tr>
<tr>
<td>• Allow Dr. Fries to work with Select Agent SEB</td>
<td>21</td>
</tr>
<tr>
<td>• Declassify <em>M. tuberculosis</em> mutants H37Rv ΔeuCD and ΔpanCD from BSL3 to BSL 2</td>
<td>22</td>
</tr>
<tr>
<td>• Guidance for poxviruses that can infect humans</td>
<td>22</td>
</tr>
<tr>
<td>• Guidance for Exposure to XDR-TB and Personnel Screening Recommendations for Exposure</td>
<td>23</td>
</tr>
<tr>
<td>o Addendum to Guidelines for XDR-TB screening and exposure</td>
<td>24</td>
</tr>
<tr>
<td>o Medical Screening Protocol for work with XDR-TB</td>
<td>25</td>
</tr>
<tr>
<td>o Post Exposure Plan</td>
<td>26</td>
</tr>
<tr>
<td>• Exception to CDC BMBL regarding ABSL 2 standards for human and non-human primate cells and tissues not experimentally infected with known infectious agents</td>
<td>28</td>
</tr>
<tr>
<td>• Minors Working with Biohazards</td>
<td>29</td>
</tr>
<tr>
<td>• Policy on Public Comments</td>
<td>32</td>
</tr>
<tr>
<td>• Template for Reporting Incidents Related to Research Subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acids to the NIH OBA</td>
<td>33</td>
</tr>
<tr>
<td>• Incident Reporting Policy</td>
<td>34</td>
</tr>
<tr>
<td>ACRONYMS</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>BSC</td>
<td>Biosafety Cabinet</td>
</tr>
<tr>
<td>BSL</td>
<td>Biosafety Level</td>
</tr>
<tr>
<td>BSO</td>
<td>Biosafety Officer</td>
</tr>
<tr>
<td>CV</td>
<td>Curriculum Vitae</td>
</tr>
<tr>
<td>DOR</td>
<td>Document of Registration</td>
</tr>
<tr>
<td>EH&amp;S</td>
<td>Department of Environmental Health and Safety</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescent Activated Cell Sorting</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IBC</td>
<td>Institutional Biosafety Committee</td>
</tr>
<tr>
<td>IRB</td>
<td>Internal Review Board</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>OBA</td>
<td>Office of Biotechnology Activities</td>
</tr>
<tr>
<td>OHS</td>
<td>Occupational Health Services</td>
</tr>
<tr>
<td>PAPR</td>
<td>Powered Air Purified Respirators</td>
</tr>
<tr>
<td>PPD</td>
<td>Purified Protein Derivative</td>
</tr>
<tr>
<td>PPE</td>
<td>Personal Protective Equipment</td>
</tr>
<tr>
<td>rDNA</td>
<td>Ribosomal Deoxyribonucleic Acid</td>
</tr>
<tr>
<td>RG</td>
<td>Risk Group</td>
</tr>
<tr>
<td>SCID</td>
<td>Severe Combined Immunodeficiency</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>XDR</td>
<td>Extremely Drug Resistant</td>
</tr>
</tbody>
</table>
INTRODUCTION

Albert Einstein College of Medicine of Yeshiva University (Einstein) is committed to conducting research in a safe and healthful manner with minimal impact on the environment. The Institutional Biosafety Committee (IBC) oversees the safe use of recombinant DNA and biohazards in research for Einstein. Einstein supports the endeavors of the IBC in promoting and ensuring that research is conducted in a safe and compliant manner.

The purpose of this manual is to assemble policies and procedural information relevant to the functions of the Institutional Biosafety Committee and to assist with the consistent and efficient operation of this Committee. This IBC Manual will be revised as needed and will be approved by a majority of voting members of the IBC.
INSTITUTIONAL BIOSAFETY COMMITTEE STATEMENT of PURPOSE

The IBC is mandated by the NIH Guidelines and acts on behalf of Albert Einstein College of Medicine of Yeshiva University to:

1. Review and support the activities of the Department of Environmental Health and Safety (EH&S) in providing guidance on the safe use, procurement, storage, and disposal of biohazards.
   a. Act as interface between the Research Faculty and the Department of Environmental Health and Safety.

2. Serve as a forum to review, make recommendations, and raise awareness related to biosafety concerns, institutional needs, emerging biosafety issues, and new biosafety requirements.

3. Review new safety and health regulations and provide guidance on their application to the Albert Einstein College of Medicine of Yeshiva University.

4. Review research activities which raise safety and/or health issues.

5. Review those engineering facilities designed to protect the worker from biohazards.

6. Review the activities of the Biohazard Facilities (BSL3).

7. Review recombinant DNA research to ensure compliance with the NIH Guidelines.
   a. Adopt emergency plans covering accidental spills and personnel contamination resulting from rDNA research
   b. Notify the Principal Investigator (PI) of the results of the IBC’s review and approval.

8. Promote a greater awareness and understanding by Faculty and Staff for the need to:
   a. Conduct all laboratory procedures and activities with attention to personal and environmental health and safety.
   b. Comply with government health and safety regulations and laws.
   c. Lower or increase containment levels for certain experiments as specified in section III-D-2-a of the NIH Guidelines.

9. Ensure that administrative controls on the use of biohazards, e.g., written guidelines, monitoring personal protection practices, etc. are available and followed.

10. Report any significant problems with or violations of the National Institutes of Health, NIH Guidelines and any significant research-related accidents or illnesses to the appropriate institutional official and NIH Office of Biotechnology Activities (OBA) within 30 days, unless the IBC determines that a report has already been filed by the Principal Investigator.
INSTITUTIONAL BIOSAFETY COMMITTEE STATEMENT of PURPOSE (cont’d)

11. Submit an annual report to NIH OBA which includes a roster of IBC members and member roles. Inform NIH OBA of members leaving the Committee or appointed to the Committee. Biographical Sketches are only sent when a new member is nominated to the Committee.

12. Recommend to the Dean (and Executive Dean) measures to decrease the exposure of the Einstein Community to biohazards.

13. Support information flow among the IBC, the Internal Review Board (IRB), and the Institutional Animal Care and Use Committee (IACUC).

14. Obtain competency training as stipulated by the NIH Guidelines.

15. Review emergent issues in biosafety.
INSTITUTIONAL BIOSAFETY COMMITTEE MEETING SUPPORT

The Department of Environmental Health and Safety provides the following in support of the IBC meetings:

1. Select the protocols to be reviewed by the Committee and develop the Agenda.
2. Work with PIs to ensure that protocols are complete before submission to the IBC for approval.
3. Collate and distribute the IBC meeting materials at least one week in advance of meetings.
4. Prepare and submit a notice for the open meeting to Public Affairs and place on Einstein’s website.
5. Take notes during the meeting to develop an accurate record of the deliberations.
6. Facilitate discussion regarding research projects and related issues.
7. Prepare the minutes of the meetings.
8. Write memos to the PIs explaining the Committee’s action on their proposal.
9. Follow up on any action requested by the Committee.
10. Draft policies for the Committee’s consideration.
11. Report on incidents, such as significant laboratory accidents and laboratory-acquired infections and violations of the NIH Guidelines and institutional policies.
12. Provide information to the IBC as needed.
13. The Biosafety Officer (BSO) will conduct annual inspections of Einstein laboratories and quarterly inspections of the Select Agent areas and report any significant findings to the IBC.
14. Keep the IBC apprised of regulatory and scientific developments that pertain to biosafety.
15. Make recommendations to the IBC.
STRUCTURE of the INSTITUTIONAL BIOSAFETY COMMITTEE

A broad array of available research and regulatory expertise is important for the IBC. The NIH requires that the IBC have at least five (5) members selected who collectively have the experience, expertise, and capabilities to assess the safety of recombinant and synthetic DNA research as well as other biological materials, agents, and organisms. The member’s training and experience should enable him/her to identify any potential risks to workers, public health, or the environment.

The IBC is composed of the following members:

1. Chairperson
2. Senior Director of EH&S (Contact Person/Administrator)
3. Non-affiliated Community Members
4. Biosafety Officer
5. Occupational Health Services Member
6. Animal Institute Expert
7. Scientific Disciplines
8. *Ex officio* members
9. Alternate members

The Executive Dean receives the minutes and all other deliberations of the IBC as needed.
APPOINTMENT PROCESS and LENGTH of SERVICE

Membership Appointments and Length of Service:

1. Candidates can be suggested by the Chairperson, Senior Director of EH&S, Biosafety Officer and/or Executive Dean.

2. Candidates receive a written communication from the Senior Executive Dean inviting them to serve on the Committee.

3. Candidates respond to the invitation in writing, either declining or accepting
   a. Copies of all correspondence are sent to the IBC Administrator of the Committee.
   b. Administrator requests CVs from the candidates
   c. Candidates’ acceptance communication and their CVs are then sent to OBA along with an updated roster of the Committee.
   d. Letter from OBA is received stating that the candidate is approved and that Einstein’s Committee is in compliance.

IBC members may serve for a 3-year period; they may elect to continue for an additional 3-year term with mutual agreement or may rotate off the Committee. There is no limitation on the length of service of public members. Ex officio members serve as long as they are in their respective positions.

Alternate members are individuals who may be appointed to the Committee as Alternates for specific IBC members. Alternate members may vote in the absence of the member to whom he/she is assigned as an alternate. The alternate should attend all meetings. An IBC member and his/her alternate may not count toward a quorum or act in any official capacity at the same time. Alternates shall receive training similar or identical to the training provided to the regular IBC members. Alternate members are included on the annual report to OBA with their role and biographical sketches.

Committee members may be asked to step down due to the following:
   1. Conflict of interest
   2. Attendance
   3. Insufficient participation
PROCEDURES for DEFINING a QUORUM

In the event that the IBC Chair must be absent, he/she will request another Committee member to serve as Chair during his/her absence. Meetings will proceed with no less than 5 voting members present, and can proceed with one more than the majority of the Committee membership. Attendance at meetings by voting members is critical. Committee members will be polled in advance of the meeting to ensure that there will be a quorum; otherwise, the meeting will be canceled or rescheduled. It is recognized, however, that members will not be able to make every meeting.

A quorum is declared at the beginning of each meeting and consists of the Committee members in attendance. Decisions such as approval of research projects or policies are approved when a majority of IBC members present vote for approval. The IBC may use consulting experts or establish working groups to execute its purpose. Consultants or working group members are not IBC voting members unless nominated and appointed as previously described.
MEETING SCHEDULE

Meetings of the IBC are scheduled for every other month and typically last one (1) to two (2) hours. Ad Hoc meetings may be called by the Chairperson when necessary. All meetings will be open to the public unless otherwise posted. Minutes, applications, attendance records, and all IBC files will be maintained by the Department Environmental Health and Safety.
MINUTES POLICY

In accordance with the NIH Guidelines, upon request, the Institution will make available to the public, all IBC meeting minutes in consultation with University Legal Counsel. Redaction of proprietary and private information is allowed but “must be done so judiciously and consistently for all requested documents” as sited in: Amy P. Patterson, MD IH Office of Biotechnology Activities, Minutes of Institutional Biosafety Committee Meetings, May 14, 2004.

Meeting minutes will be reviewed, approved by the members and signed by the Chairman; if Chairman is not present, an appointed IBC member shall sign. Minutes are submitted for approval at the next convening meeting of the IBC.
CONFLICT of INTEREST POLICY

It is the policy of this Committee that no member of the IBC may be involved (except to provide information requested by the IBC) in the review or approval of a project in which he/she has been, or expects to be engaged, or has a direct financial interest. The member may remain in the meeting room during the deliberation but may not serve as a reviewer and must abstain from offering comments unless called upon to answer a question or provide clarification. The member must abstain from voting on the motion. Each member is expected to notify the IBC Chair in these circumstances and recues themselves when such proposals are being discussed and are up for a vote. In addition, if the IBC Chair is Principal Investigator on a project, another IBC Committee member present at the meeting will sign the approval form if the project is approved.
PROTOCOL REVIEWS

The administrative function of the IBC will be handled by EH&S. Meeting materials are prepared and distributed by EH&S at least one week in advance of the meetings. Protocol copies are provided to all IBC members at this time. The agenda is also distributed to the members at least one week before the meeting.

Principal Investigators may be contacted, brought before the Committee or placed “on call” if additional information or clarification is needed to complete risk assessments and facilitate discussion. Protocols are submitted well in advance of the IBC meeting date to allow time to address outstanding issues. Protocols that require review by the IBC cannot be expedited.

Actions by the IBC on a protocol typically involve one or a combination of the following decisions:

1. Approve – the protocol is accepted as provided to the Committee

2. Delegated Review – requires the PI to take additional steps before the protocol will be approved. Typically, the protocol must be revised to the satisfaction of the BSO and/or reviewers.

3. Table – the protocol has significant deficiencies that must be addressed before the Committee will reconsider it.

4. Reject – this action is indicative of significant problems with the protocol.

All recombinant DNA work, work involving the use of microorganisms pathogenic to humans or animals, and any work with Select Agents and Toxins at Einstein will be initially registered through EH&S. There is a special form for this registration.

1. All recombinant DNA research, including exempt research will be submitted to the IBC for approval. Recombinant DNA research will be reviewed as follows:

   a. A Document of Registration (DOR) will be completed by the Principal Investigator for their research and provided to the BSO for review.

   b. The BSO will provide the project with a pending protocol number, provide a biosafety level and enter the registration information into a computer database.

   c. If the project involves Risk Group (RG) 2 agents or above, a letter or notation on the DOR will accompany the DOR sent back to the PI to let them know that the project is pending IBC approval.

   d. A DOR spreadsheet is provided to the IBC members before each meeting. With a quorum present, the DORs are discussed, approved, delegated, or rejected.
PROTOCOL REVIEWS (cont’d)

e. DORs are valid for a period of three years unless there has been a change in the rDNA research in which case, the PI must complete a new DOR. DORs expire on December 31\textsuperscript{st} of the third year.

f. At the beginning of each calendar year, the PI is asked to renew the signature on the DOR to verify that no changes have occurred throughout the year.

g. Once the IBC has reviewed a project, a letter or e-mail will be sent to the PI stating that the project has been reviewed by the IBC and the project is approved, delegated, tabled or rejected.

h. No work will commence prior to the approval of the “Application for Laboratory Registration, Use and Transfer of Select Agents and Toxins”.

2. Work involving the use of microorganisms pathogenic to humans or animals will be reviewed as follows:

a. A DOR which lists the microorganisms will be completed by the PI for their research and provided to the BSO for review.

b. The BSO will provide the project with a pending protocol number, provide a biosafety level and enter the registration information into a computer database.

c. If the project involves RG2 microorganisms or above, a letter or notation on the DOR will accompany the DOR sent back to the PI to let them know that the project is pending IBC approval.

d. A DOR spreadsheet listing all microorganisms is also provided to the IBC members before each meeting. With a quorum present, the DORs are discussed, approved, delegated or rejected.

e. DORs are valid for a period of three years unless there has been a change to the research in which case, the PI must complete a new DOR. DORs expire on December 31\textsuperscript{st} of the third year.

f. At the beginning of each calendar year, the PI is asked to renew the signature on the DOR to verify that no changes have occurred throughout the year.

g. Once the IBC has completed review of a project, a letter or e-mail will be sent to the PI stating that the project has been reviewed by the IBC and that the project is approved, delegated, tabled, or rejected.
PROTOCOL REVIEWS (cont’d)

3. Work involving the use of Select Agents and Toxins will be reviewed as follows:
   a. The PI will complete a form indicating their proposed plan for working with Select Agents or Toxins.
   b. The Executive Dean will be consulted and his/her approval will be sought before proceeding with the IBC approval.
   c. The IBC will review and approve, delegate or reject registration of Select Agents and Toxins at a convened meeting.
   d. The PI will be notified in writing of the IBC’s decision.
   e. If approved, the “Application for Laboratory Registration for Possession, Use and Transfer of Select Agents and Toxins” will be initiated by the PI and EH&S.
   f. No work will commence prior to approval of the “Application for Laboratory Registration for Possession, Use and Transfer of Select Agents and Toxins”.

4. Approval of Biohazard Use in Animals - The IBC will not duplicate the work of the IACUC in dealing with animal welfare issues; instead it is to concentrate on evaluating the risks of biohazards in research animals and associated worker.
   a. If an investigator is placing biohazard agents or materials including rDNA into an animal, he/she must list the agent in the appropriate Appendixes of the Animal Protocol. Once the Animal Protocol is complete, the PI submits the original and at least one copy of the Animal Protocol to the BSO for approval.
   b. Once approved by the BSO, the PI will submit the original Animal Protocol to the IACUC office where it will be reviewed by members of the IACUC and then presented for full IACUC review.
   c. If the BSO does not approve the biohazard agents or material including rDNA work in the PI’s Animal Protocol, the protocol will need to get IBC approval before the IACUC can approve.
   d. The IACUC secretary will on a bi-weekly basis provide EH&S with protocol profiles of all Animal Protocols that contain all hazards. The BSO reviews all Animal Protocols and determines which profiles contain biohazards and provides these protocols to the IBC Administrator. The Administrator distributes the profiles along with a comment sheet to all the IBC members.
e. The Committee members’ comments are returned to the Administrator who provides them to the BSO at which time each protocol is evaluated. The possible outcome of the comments are as follows:

i. Full Committee Review – any member can call for a full Committee review. The protocol is presented and discussed at the next IBC Meeting.

ii. Clarification – requests for clarification are made on the comment sheets; the BSO addresses all comments at the next IBC Meeting.

iii. Delegated Review – a vote by mail by our IBC members stating that the reviewer has read the Animal Protocol and they are authorizing the BSO to review and approve the protocol on their behalf. The delegated review list is then presented at the IBC Meeting and entered into the minutes.

f. The IACUC Office will be notified of the IBC’s protocol review via the distribution of the IBC minutes which will be supplied by EH&S.
LABORATORY CONTAINMENT and SAFETY

The PI must verify that all staff members conducting research with BSL 2 or BSL 3 organisms or biological material including rDNA are properly trained, have attended training and are following all the procedures required by the regulations, i.e., his/her lab or EH&S. The PI has the immediate supervisory worker responsibility and must inform the laboratory staff of any hazards associated with their work and providing guidance on how to work safely. The PI is responsible for immediate notification to the BSO of any accidents or incidents involving viable infectious organisms.

The PI is responsible for ensuring that laboratory staff is working in the proper level of containment and with the proper personal protective equipment (PPE) at all times. The PI is also responsible for ensuring the Biosafety Cabinet (BSC) is certified on an annual basis and is operational.
HEALTH SURVEILLANCE PROGRAM

The Albert Einstein College of Medicine has established and maintained a health surveillance program for personnel engaged in activities involving BSL 2 and BSL 3 activities with viable infectious organisms or rDNA. Further details of the health surveillance program can be obtained from Occupational Health Services.
INSTITUTIONAL BIOSAFETY COMMITTEE VOTING

The following is the process for IBC voting:

1. Agenda item is presented followed by Committee discussion
2. Motion to accept or deny approval is made
3. Motion is seconded
4. All in favor is presented; all opposed is presented
5. Majority is accepted
6. Abstains or objections are noted.
PROTECTING CONFIDENTIAL INFORMATION

Protocols may contain information that must be patent protected due to the impact of disclosure on the ability to publish the information or because of patient privacy. In addition, protocols may require protection to ensure the safety and security of research facilities, materials and personnel, or because the information is deemed patent protected and subject to nondisclosure agreements. Every protocol is assumed to contain confidential information and release of copies to an individual outside of the Committee may be done only with the permission of the PI. Copies of protocols may be retained by Committee members and consultants, but they must be destroyed (e.g., shredded) prior to disposal.
INSTITUTIONAL BIOSAFETY COMMITTEE MEMBERSHIP

Chair –
  Dr. Harris Goldstein – Professor of Pediatrics/Allergy and Immunology

Non-Affiliated Community Members
  Anthony J. Taranto, HEM – Assistant Administrator of Supporting Service, Calvary Hospital
  Madeline Provenzano – NYC Council Member 13th District of Bronx, NY (retired)

Institutional Biosafety Officer –
  Delia Vieira-Cruz – Laboratory Safety Officer and Biosafety Officer

Occupational Health -
  Tina Crane, RN

Contact Person and Administration Representative –
  Anthony Chibbaro – Senior Director, Department of Environmental Health and Safety

Animal Expert –
  Dr. Lawrence Herbst – Director of Institute for Animal Studies

Membership:
  Dr. Michela T. Catalano – Director, Occupational Health Service, Montefiore Medical Center
  Dr. Bing Chen – Associate Dept of M&I and Director BSL3 Facility, Howard Hughes Medical Institute
  Dr. Ekaterina Dadachova – Associate Professor, Nuclear Medicine/ Microbiology and Immunology
  Mr. Garrett T. Doering – Montefiore Director, Department of Environmental Health and Safety, Montefiore
  Dr. Amy Sue Fox – Director, Virology Laboratory
  Dr. Sanjay Goel – Montefiore, Associate Professor of Medicine, Oncology
  Dr. William Jacobs – Professor of Microbiology/Immunology and Molecular Genetics
  Dr. Joshua D. Nosanchuk – Associate Professor of Medicine and M&I
  Dr. Vinayaka R. Prasad – Professor of Microbiology and Immunology
  Dr. J. Roy-Chowdhury – Professor of Molecular Genetics and Professor of Medicine
  Dr. Louis Weiss – Professor of Pathology and Professor of Medicine and M&I

Ex Officio Members:
  Dr. Edward Burns – Executive Dean
  Mr. John Harb – Assistant Dean for Scientific Affairs
  Ms. Barbara Levy – Assistant Dean for Academic Affairs
  Mr. John Scarfone – Legal Counsel
INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES

- Approval by IBC to move intravenous infected *M. tuberculosis* mice from BSL 3 to BSL 2 within the Biohazard Facility [IBC Meeting, October 23, 2003]

- Approval by IBC to declassify *M. tuberculosis* mutants MC²6030 and MC²60020 from BSL 3 to BSL 2: Dr. Jacobs presented scientific data demonstrating the mutant strains to be safer than BCG. After much discussion, the IBC approved the declassification of MC²6030 and MC²60020 from BSL3 to BSL2 with the stipulation that all new mutants be presented to the IBC with safety data [IBC Meeting, May 17, 2004].

- The IBC offered guidance for in-servicing of the Madison Wisconsin Chamber to include:
  - Plate monitoring every six months to ensure functioning containment
  - Visual and soap solution checks of the transparent tubing to check for damage.
  - Hose markings to ensure tubing direction
  - Log book of all testing and maintenance performed on the Madison Wisconsin Chamber [IBC Meeting, August 16, 2005].

- Approval by IBC to allow Dr. Casadevall to work with Select Agent, *Bacillus anthracis* Sterne Strain [IBC Meeting, August 16, 2005].

- Approval by IBC to allow Dr. Casadevall to work with Select Agent, *Bacillus anthracis* Pasteur Strain [IBC Meeting, September 19, 2006].

- The IBC offered the following guidance in FACS sorting unfixed cells [IBC Meeting, December 9, 2008]. At a minimum, the IBC agreed that anyone entering a room where unfixed cells were being sorted must:
  - Don an N-95 respirator
  - Operators of the cell sorter are encouraged to use powered air purifiers (PAPRs)
  - All employees in the room wear gloves and disposable gowns.

- Approval to allow Dr. Kielian to continue working with Semliki Forest virus at an enhanced BSL2 containment in a biosafety hood located in a dedicated negative pressure and access controlled room [IBC Meeting, December 9, 2008].

- Approval by the IBC to allow Dr. Fries to work with Select Agent, *Staphylococcus Enterotoxin B* [IBC Meeting, January 29, 2010].
INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES

- Approval by the IBC to declassify *M. tuberculosis* mutants H37Rv ΔeuCD and ΔpanCD from BSL 3 to BSL 2. Dr. Jacobs has found that these new strains are more attenuated than previous strains. With the previous strains H37Rv, SCID mice would succumb in 25 days at a dose of $10^5$ CFUs. For *M. bovis*, the vaccine strain SCID mice would succumb in 140 days at $10^5$ CFU and 220 days at a dose of $10^4$. In contrast, SCID mice infected with $10^5$ CFU of *leuCD panCD* double auxotroph mc^26206 survival at 250 days [IBC meeting, March 11, 2010].

- Guidance provided by the IBC on appropriate precautions for work with poxviruses that can infect humans, recommendations for containment and vaccination. Approval of Vaccinia Handout “Vaccinia Virus Use and Immunization Policy for Laboratory Personnel” [IBC Meeting, March 11, 2010].
INSTITUTIONAL BIOSAFETY COMMITTEE
OPERATIONAL HANDBOOK

INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES

- Guidelines for Exposure to XDR TB and Personnel Screening Recommendations for Exposure
  Proposal and approval to work with multiple drug-resistant and extensively drug-resistant *M. tuberculosis* strains in the Jacobs’ Biosafety Level 3 (BSL 3) Laboratory in the Price Center.
  - A major concern is expanding their work to include XDR strains
  - Closer monitoring of the workers was suggested using Quantiferon Gold and for employees to be monitored quarterly instead of bi-annually
  - A surveillance and exposure plan must be developed
  - Engineering controls need to be finely defined to limit exposure of personnel to the strain. No traffic should be allowed in the area other than employees working on the project.
  - Animal caretakers should be part of the quarterly monitoring and should be provided with PAPRs. There should be limited access when changing animal bedding.
  - PAPRs are required for entrance into animal room
  - Information should be clear regarding where PAPRs will be stored
  - The Jacobs’ lab should post their spill response to existing procedures.
  - A post-exposure hotline must be posted in all labs using XDR TB. Post-exposure therapy will be based on the assessment of exposure by OHS in coordination with TB experts. Employees with +PPD or other TB screening test and negative chest X-rays will have clinical assessments more frequently. Employees with HIV infection or other immuno-compromised candidates should not be working with the XDR TB.
  - Dr. Jacobs and M. Larson will speak with the caretakers before they begin work. All caretakers will need PAPRs.
  - There will be screening available for Engineering or any other staff who need access to the rooms. They will require PAPRs. It was felt that we will follow the standard protocol which is currently in place for additional staff entering the TB rooms.
  - For any ongoing screening for TB acquisition, employees will have their symptoms checked every 3 months and a chest X-ray for active disease.
  - Visiting scientists will be partnered with a senior member of the lab and will be tested and have Quantiferon Gold available to them.
  - Occupational Health Services and the BSO will be informed of any change in personnel.
  - PAPRs for non-lab personnel will be provided by Dr. Jacobs. There will be a sign posted on the door stating that PAPRs are required for entry.
  - Spill procedures should be reviewed by the lab workers before work begins. Spot D-con will first be considered with the option to decontaminate the entire room if needed.
  - A motion was made and seconded to approve Dr. Jacobs’ work to allow XDR TB strain to be used with the modification that Employee Health creates final documents. It was passed unanimously by the members present with Dr. Jacobs abstaining from voting [IBC Meetings, January 28, 2010 and March 11, 2010].
INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES (cont’d)

- Addendum to Guidelines for Exposure to XDR TB and Personnel Screening
  Recommendations for Exposure:
    - Sub-Committee made up of members, J. Nosanchuk, L. Weiss and M. Catalano
      provided the following:
        - In a prominent space in the lab, POST sensitivities of organisms being used.
        - Monitor lab workers with periodic screening
        - Tuberculin test conversions will be evaluated and treatment offered in the
          following manner:
          - Routine conversion detected as part of the screening program will
            address INH and linezolid or quinolone will be offered addressing
            both susceptible and XDR organisms.
          - Conversion after a known laboratory exposure will address only the
            laboratory strain.
          - If catastrophic event occurs, i.e., massive aerosolization of XDR TB
            organisms, the policy will be to hospitalize those exposed and then
            treat them with appropriate (multiple) antibiotics including per
            intravenous route.
    - Since baseline Quantiferon tests have been completed the IBC unanimously
      agreed to change the screenings from three months to six months for workers
      handling XDR TB. For those employees who have a history of positive PPD and
      positive Quantiferon, a signs and symptoms of TB check will be done every six
      months. For new workers the XDR TB lab, baseline PPD skin testing and a
      Quantiferon blood test will be performed before their being permitted to enter the
      lab.
    - A motion was made and seconded to put this policy into effect. It was passed
      unanimously by the members present. [IBC Meetings, November 11, 2010.]
Medical screening protocol for work with XDR TB

All approved individuals who will be either working directly with XDR TB, or who will have access to the laboratory where XDR TB is contained, MUST be medically screened prior to any possible laboratory exposure.

A designated person in the TB facility must be responsible to inform the Occupational Health Service (OHS) of those individuals who will have access to the laboratory so that pre-exposure screening can be conducted and medical clearance given BEFORE being permitted to enter the laboratory. Also, a designated person in the Institute for Animal Studies, Custodial, Engineering, Sue Golding Graduate Division, and all other appropriate departments, must be responsible to inform the Occupational Health Service of those individuals who will need medical clearance prior to any laboratory exposure.

All personnel must receive medical clearance PRIOR TO receiving respirator FIT training from the Environmental Health and Safety Office (EHS). Each person who has received medical clearance will receive written documentation from the Occupational Health Office that must be presented to the EHS Office, before respirator FIT training can be conducted.

A baseline Interferon Gamma Release Assay (IGRA) for tuberculosis will be performed on each individual prior to any laboratory exposure. Also, a voluntary HIV test will be offered to each individual prior to laboratory exposure. All results will be kept as part of the individual’s confidential medical record in the Occupational Health office. Those individuals who are HIV infected should not work with XDR-TB.

For any individual who does not have a baseline medical record that includes tuberculosis screening, currently in the OHS, baseline blood tests and a physical examination will be performed in addition to the pre-exposure IGRA.

If any individual tests positive by IGRA standard, prior to any laboratory exposure, appropriate follow-up will be made and evaluation for active disease will be performed. A signs and symptoms of TB questionnaire will be completed and appropriate treatment options will be offered to the individual. The individual will be screened every six (6) months for signs and symptoms of TB.

A PPD skin test will be performed on those with a NEGATIVE PPD history every six (6) months, and a SIGNS AND SYMPTOMS OF TB QUESTIONNAIRE WILL BE COMPLETED EVERY 6 MONTHS for those with a positive history. Non-compliance will be reported to the individual’s direct supervisor and EHS and a recommendation for removal from the laboratory will be made until appropriate screening is performed.

All changes in medical status i.e.- pregnancy, cancer, immunosuppression, use of steroids, TNF-alpha inhibitors, chemotherapeutic agents, etc. should be reported to the Occupational Health Service immediately.

The Occupational Health Service Exposure Hotline # 1-917-729-0438 should be posted in the laboratory. This is a 24hr/7day service that should be accessed after normal business hours if an exposure is suspected. ALSO THE LIST OF TB STRAINS CONTAINED IN THE LAB SHOULD BE POSTED IN THE LAB.

When an individual who has worked in the XDR-TB laboratory is leaving Einstein, it is the responsibility of the individual’s primary department to inform the Occupational Health Service of such, at least one week before the individual leaves Einstein, so that an exit TB exposure evaluation may be performed.
Post-exposure plan

Anyone who has laboratory exposure who has a change in PPD skin test from negative to positive will be notified immediately and removed from the laboratory. Also, those individuals with a history of a positive PPD skin test and negative chest x-ray who report symptoms of TB will be removed from the laboratory. In both instances, post-exposure referral for medical follow-up will be initiated immediately and appropriate treatment options will be made available to the affected individual, including completion of a signs and symptoms of TB questionnaire, chest x-ray and physical examination. Appropriate post-exposure follow-up instructions will be given. A list of sensitivities and specifics regarding drug treatment regimens will be available in the laboratory and a copy of such should be given to the individual to bring to the initial post-exposure follow-up evaluation.

Any accidental exposure that occurs in the laboratory must be reported to the Occupational Health Service (OHS) and Environmental Health and Safety Office (EHS) immediately. Appropriate post-exposure evaluation will commence immediately. If the accident/exposure happens before or after normal business hours, the Occupational Health Service Exposure Hotline should be called at 1-917-729-0438. This is a 7 day a week/24 hour a day service.

The affected individual should go to the Weiler ER accompanied by the list of drug sensitivities. Specifics regarding treatment regimens will be available in the laboratory.

Guidelines for PPD Conversion in a Laboratory Employee

Tuberculin skin test conversions will be evaluated and treatment offered in the following manner:

1. Routine conversion detected as part of the screening program will address both community and occupationally acquired infection. Dual therapy with INH and linezolid or a quinolone will be offered addressing both susceptible and XDR organisms.

2. Conversion after a known laboratory exposure will address only the laboratory strain.

3. If a catastrophic event occurs i.e. massive aerosolization of XDR TB organisms, the policy will be to hospitalize those exposed and treat with appropriate (multiple) antibiotics including per intravenous route.

Guidelines for Follow-up of Active TB in a Laboratory Employee

Response to therapy will be monitored by the treating physician by collecting sputum samples monthly for the course of treatment, (usually 18-24 months after cultures convert to negative.) Monitoring should continue several times a year for 2 years after the completion of therapy in order to observe for relapse.
Anyone who has positive sputum smears and/or positive sputum cultures will be cleared to return to work only after the sensitivities of their organism are known and their medical regimen adjusted accordingly:

a) For multiple drug-resistant tuberculosis, individuals must demonstrate three (3) consecutive negative sputum cultures (final report) on appropriate therapy and clinical improvement or radiographic improvement of their pulmonary infiltrate.

b) Strong consideration should be given to enrolling all individuals with tuberculosis in directly observed therapy (DOT)

c) Whether individuals have patient contact should be considered in all cases before the decision is made to return them to work

d) All individuals with active tuberculosis will be offered HIV counseling and testing.
INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES (cont’d)

• Exception to CDC Biosafety in Microbiological and Biomedical Laboratories (BMBL) Manual regarding ABSL-2 standards for human and non-human primate cells and tissues not experimentally infected with known infectious agents.

The IBC was asked by Dr. Herbst to vote on whether the mice infected with human cells can remain in the current animal rooms which are not under negative pressure. A motion was made that the mice infected with human cells can remain in the current animal rooms which are not under negative pressure.

A motion was made and seconded to accept this policy. It was passed unanimously by those members present. [IBC Meetings, November 11, 2010].
INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES (cont’d)

- Minors working with biohazards

INSTITUTIONAL BIOSAFETY COMMITTEE
of ALBERT EINSTEIN COLLEGE of MEDICINE of YESHIVA UNIVERSITY

GUIDELINES for MINORS WORKING in LABORATORIES

ALL MINORS who want to/VOLUNTEER in a laboratory MUST:
- REGISTER THROUGH HUMAN RESOURCES,
- BE CLEARED BY THE OCCUPATIONAL HEALTH SERVICE.
- BE TRAINED IN ACCORDANCE WITH ALL APPLICABLE regulatory and institutional GUIDELINES FOR LABORATORY WORKERS
- CARRY A VALID ID CARD.

ONCE ALL THIS IS IN PLACE, THE FOLLOWING GUIDELINES MUST BE FOLLOWED.

Volunteers 18 Years of Age or Older
- No restrictions

Volunteers 16 or 17 Years of Age
- Volunteers must obtain a signed form releasing Einstein from potential liability with a parent or guardian signature. The form titled "Student/Volunteer Release Form/Affidavit of Supervision", a copy of which is attached, is a triplicate form which is obtained from Human Resources. When completed, the white copy is sent back to HR, the yellow copy is sent to Occupational Health and the pink copy is sent to Environmental Health and Safety. The form must include a description of the work in which the volunteer will be involved and a signature of the Principal Investigator and parent or guardian of the minor.
  - Volunteers in laboratories supported by an outside entity such as Howard Hughes Medical Institute must obtain a written consent from the outside entity.
- Volunteers must be continuously supervised by either the Principal Investigator or a designated competent substitute.

Prohibitions:
- Volunteers may not prepare any composition in which dangerous or poisonous acids are used unless (s)he has completed a training program given by a public school or nonprofit institution which includes safety instruction approved by the Commissioner of Labor.
- Volunteers may not work in a BSL-3 facility, or with any of the following: radiation, hazardous chemicals, animals or exposure to silica or other harmful dust.

Hours:
- When school is in session, we recommend that volunteers, consistent with New York State Department of Labor restrictions, work a maximum of:
  - 28 hours per week
  - 8 hours per day on Friday, Saturday, Sunday or a holiday
  - 4 hours per day on Monday through Thursday
- Volunteers should not work between 10:00PM and 6:00AM
- When school is not in session and during school vacations lasting at least one week, volunteers may work a maximum of:
  - 6 days/48 hours per week
  - 8 hours per day between the hours of 6:00AM and 10:00PM

Volunteers Under 16 Years of Age
- Volunteers under 16 years of age in high school will be considered on a case-by-case basis by the IBC or its designate. The Principal Investigator in whose lab the minor will volunteer/work should contact Anthony Chibbaro (718 430-4150) or Delia Vieira-Cruz (718 430-3560) for this determination.
INSTITUTIONAL BIOSAFETY COMMITTEE POLICIES (cont’d)

PART A

Student/Volunteer Name: * ________________________________________________________
Address: _________________________________________________________________________
Telephone #: _______________________________________________________________________
SS#: ______________________________________________________________________________

1. I, __________________________________ am working/volunteering in ______________________________
   Print Name                          Department
   of the Albert Einstein College of Medicine of Yeshiva University. In this capacity my duties may include but may not be limited
   to _________________________________________________________________
   _________________________________________________________________________
   _________________________________________________________________________

2. I hereby release from liability and hold harmless Yeshiva University, the Albert Einstein College of Medicine of Yeshiva University
   (AECOM), and their trustees, officers, employees, faculty, students and agents from and against any claims damages, suits costs, or
   expenses I may have for any injury relating to or arising out of my service as student/volunteer in the ________________________________
   laboratory at AECOM.

* IF THE STUDENT/VOLUNTEER IS UNDER 18 YEARS OF AGE, HE/SHE IS CONSIDERED A MINOR AND A PARENT,
  OR GUARDIAN MUST SIGN.

PART B

We will ensure that the student/volunteer __________________________________, who will be working or training in our laboratory
from ____________ to ____________, will receive safety orientation and will be under supervision while at work in our laboratories.

________________________________  _______________________________  ____________
Name of Lab Director             Signature of Lab Director                             Date

________________________________  _______________________________  ____________
Name of Student/Volunteer            Signature of Student/Volunteer           Date

Date of Birth           Signature of Parent or Guardian                      Date
of minor Student/Volunteer

OHS - White          HR -Pink       Safety-Yellow
A discussion ensued and guidelines were set as stated above in the GUIDELINES for MINORS WORKING in LABORATORIES and STUDENT/VOLUNTEER RELEASE FORM/AFFIDAVIT OF SUPERVISION; in particular, that volunteers under 16 years of age in high school will be considered on a case-by-case basis by the IBC or its designate.

A motion was made and seconded. It was passed unanimously by the members present. [IBC Meetings, November 11, 2010.] The guidelines will be published to the Einstein Community through an e-mail sent by the Senior Director of Environmental Health and Safety to all faculty members.
IBC POLICY ON PUBLIC COMMENTS

In accordance with the NIH Guidelines, Albert Einstein college of Medicine will, upon request, make available to the public, all IBC meeting minutes in consultation with University Legal Counsel. Redaction of proprietary and private information is allowed but “must be done so judiciously and consistently for all requested documents” as sited in: Amy Patterson, MD IH Office of Biotechnology Activities, Minutes of Institutional Biosafety Committee Meetings, May, 14, 2014.

If public comments are made on Institutional Biosafety Committee actions, the institution shall forward both the public comments and the Institutional Biosafety Committee’s response to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non USPS mail), 301-496-9838, 301-496-9839 (fax).

Requests for minutes should be directed to the Senior Director of Environmental Health and Safety at the following address:

   Senior Director
   Department of Environmental Health and Safety
   Albert Einstein College of Medicine
   1300 Morris Park Avenue, Forchheimer 800
   Bronx, NY 10461

If public comments are made on Institutional Biosafety Committee actions, the Chair of the Institutional Biosafety Committee will forward all comments and the Institution’s response to the NIH Office of Biotechnology Activities at the below address:

   National Institutes of Health
   6705 Rockledge Drive, Suite 750, MSC 7985
   Bethesda, MD 20892 (20817 for non UPS mail)
# NIH OBA Incident Reporting Template

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes/No</th>
<th>Date/Number/Email</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does this incident involve research subject to the NIH Guidelines?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, this incident does not have to be reported to OBA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Institution name: Albert Einstein College of Medicine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reporter name and position:</td>
<td></td>
<td>Reporter telephone:</td>
<td></td>
</tr>
<tr>
<td>Reporter mailing address:</td>
<td></td>
<td>Reporter email Address:</td>
<td></td>
</tr>
<tr>
<td>Date of the incident:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator (Last Name, First Name):</td>
<td></td>
<td>Telephone Number</td>
<td></td>
</tr>
<tr>
<td>Principal Investigator email:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is this an NIH funded project?</td>
<td></td>
<td>NIH Grant or contract number:</td>
<td></td>
</tr>
<tr>
<td>If yes, please provide:</td>
<td></td>
<td>NIH funding institute or center:</td>
<td></td>
</tr>
<tr>
<td>NIH program officer contact information (name, email etc):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What was the nature of incident?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personnel exposure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spill</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss of containment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss of transgenic animal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure to obtain IBC approval</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure to follow approved containment conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other - please describe:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the Institutional Biosafety Committee (IBC) approve this research?</td>
<td></td>
<td>DOR #</td>
<td></td>
</tr>
<tr>
<td>Approval date:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approved Biosafety level for the research:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BSL 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BSL 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BSL 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional approval requirements:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What section(s) of the NIH Guidelines is the research subject to?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IID</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Has a report of this incident been made to other federal or local agencies?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research funding agency/sponsor: (name)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State/Local public Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Federal/State/Local law enforcement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other - Please describe:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Please complete the following questions about the incident in sufficient detail to allow for an understanding of the nature and consequences of the incident. Use additional space as necessary.

1. Description of recombinant or synthetic agent or material involved (please indicate strain, attenuation etc.)

2. Provide the incident/violation location.

3. Who was involved in the incident/violation, including others present at the incident location? Include position titles (e.g., graduate student, post doc, animal care worker, etc).

4. Actions taken immediately following the incident/violation, and by whom, to limit any health or environmental consequences of the event.

5. List relevant training received by the individual(s) involved and the date(s) the dates training was conducted (include training by the PI, EH&S, other online training as applicable).

6. Does the laboratory have standard operating procedures (SOPs) for the research? If so, was there any deviation from these SOPs at the time of the incident/violation? □ yes □ no

7. Was there a deviation from the IBC approved containment level or other IBC approval conditions at the time of the incident/violation? □ yes □ no

8. List the personal protective equipment in use at the time of the incident/violation.

9. Was there any equipment failure? □ yes □ no

10. Was there any injury or illness associated with the incident? □ yes □ no

11. What are the occupational health requirements for the laboratory personnel involved in the research?
12. Was there any medical advice/treatment/surveillance provided or recommended after the incident?  
☐ yes  ☐ no

13. Are medical surveillance results available (if not available at the time of initial report please indicate when results will be available)?  ☐ yes  ☐ no

14. Provide a brief summary of the incident:

15. Has the IBC reviewed this incident?  ☐ yes  ☐ no  
   If yes, please provide a copy of the IBC meeting minutes which the incident was reviewed.

16. Has a root cause for this incident been identified?  ☐ yes  ☐ no  
   If yes, please describe:

17. Describe measures taken by the PI and the laboratory to mitigate any problems identified. For measures identified but not yet implemented, please include a timeline for their implementation: (use additional space as necessary)

Principal Investigator Signature

Date
“The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) states that "...any significant problems, violations of the NIH Guidelines, or any significant research-related accidents and illnesses" must be reported to NIH OBA within 30 days. Certain types of accidents must be reported on a more expedited basis. Spills or accidents in BSL2 laboratories resulting in an overt exposure must be immediately reported to NIH OBA. Spills or accidents occurring in high containment (BSL3) laboratories resulting in an overt or potential exposure must be immediately reported to NIH OBA”.

Principle Investigators must ensure all laboratory personnel know when to seek medical attention and how to report an incident. Laboratory personnel should seek medical attention, when necessary and report all incidents to the Principle Investigator and Environmental Health and Safety (x4150).

Type of accidents to report to NIH OBA:
- Any spill or accident involving recombinant or synthetic nucleic acid research that leads to personal injury or illness
- A breach of containment
- Skin punctures with needles containing recombinant DNA
- Escape or improper disposition of a transgenic animal
- Spills of high-risk recombinant or synthetic materials occurring outside of a biosafety cabinet.
- Failure to adhere to the containment and biosafety practices articulated in the NIH Guidelines.

Minor spills of low-risk agents not involving a breach of containment that were properly cleaned and decontaminated generally do not need to be reported but should be reported to EH&S for final determination.

Any exposure of a BSL 2 or 3 agents by inhalation, inoculation, ingestion, or skin contact (including bites, cuts and wounds) must be referred to a physician, reported to the individual’s supervisor and to EH&S (718-430-4150) within 24 hours.

For Injuries involving biohazardous agents or materials including recombinant or synthetic nucleic acid molecules:
- Immediately wash the site thoroughly with soap and water, and flush mucous membranes with water/saline for at least 15 minutes.
- Notify PI and EH&S (x4150) (EH&S can be contacted after hours by calling x4111).
- If medical attention is necessary visit:
  - Between 8AM and 4PM visit Occupational Health Services clinic, located at 1180 Morris Park Avenue, 1st floor for evaluation and treatment or go to the nearest Emergency Room.
  - All hours, go to the nearest Emergency Room for evaluation and treatment.
- Within 24 hours, contact EH&S (718) 430-4150 to fill out NIH OBA Incident Report.
- EH&S, who will report the incident, to the Institutional Biosafety Committee (IBC) and to the Office of Biotechnology Activities (OBA) immediately for overt exposure or within 30 days for others.

For more information on incident reporting visit: